Frontier Medicines’ integrated approach leverages chemoproteomics and machine learning to accelerate the development of medicines that drug the “undruggable” protein targets that drive human disease.
Frontier Medicines is discovering and developing breakthrough medicines that redefine the course of debilitating diseases.
Media Coverage
September 23, 2019
FierceBiotech: FierceBiotech Names Frontier Medicines One of Its “Fierce 15” Biotech Companies of 2019
Read article
June 26, 2019
WSJ Venture Capital: Biotech Entrepreneur Chris Varma Scores $67 Million for Frontier Medicines
Read article
June 26, 2019
Fierce Biotech: Frontier Medicines Launches with $67M and Biotech Veteran Varma as CEO
Read article
June 26, 2019
BioWorld: Frontier Medicines Launches with a $67M Series A Round
Read article
June 26, 2019
BioCentury: Frontier Aims for Previously Unreachable 'Hot Spot' Targets with $67M Series A
Read article
June 26, 2019
C&EN: Frontier Medicines Launches with $67 Million in Funding
Read article